MA-FORRESTER
25.6.2024 15:01:32 CEST | Business Wire | Press release
According to Forrester’s (Nasdaq: FORR) The Top 10 Emerging Technologies In 2024 report, generative AI (genAI) for visual content, genAI for language, TuringBots, and IoT security are the top emerging technologies that will deliver the most immediate ROI for businesses in 2024 and beyond.
With new technologies emerging seemingly every day, business and technology leaders need to time those investments based on value, risk, and potential payout timelines. Forrester organizes its top emerging technologies by benefit horizon to help with these decisions.
Emerging technologies that will offer significant benefits within the next two years:
- GenAI for visual content. Advanced machine learning models that generate images or video from text, audio, or video prompts, this technology will help firms generate visual content for marketing, experiences, and products.
- GenAI for language. GenAI for language is already delivering value in customer support and content creation but continues to advance at a blinding pace. It is accelerating many other technologies as it goes.
- TuringBots. Accelerated by advancements in genAI for language, these AI-powered software robots help developers build applications that deliver more than just code generation.
- IoT security. The proliferation of devices has led to an exponential explosion in security attacks, raising the importance of security for IoT devices. Vendors are competing and colliding in a rush to offer capabilities.
Midterm emerging technologies that will deliver benefits in the next two to five years:
- AI agents. The role of autonomous workplace assistants or AI agents has expanded beyond the back office and employee assistance to customer-facing automation. These AI agents will grow increasingly sophisticated to better understand and respond to nuance and context.
- Autonomous mobility. This technology will accelerate commercial and urban transportation ecosystem collaborations to orchestrate personalized mobility experiences for both customers and businesses.
- Edge intelligence. Advanced edge intelligence capabilities such as edge machine learning are still not yet common, even though many foundational elements like Apple foundation models are becoming available.
- Quantum security. This technology will overhaul security systems for on-premises and cloud compute, storage and network infrastructure, commercial off-the-shelf software, commercial software-as-a-service offerings, and in-house built software.
Emerging technologies that will take at least five more years to deliver tangible value for most firms and use cases:
- Extended reality (XR). Only 8% of US online adults own a virtual-reality headset, and just 16% have used an augmented-reality device or app. While XR is advancing in training and onboarding, companies are resisting investing in tools like these until they see broad adoption.
- Zero Trust edge (ZTE). ZTE technology has the potential to protect remote workers, retail outlets, and branch offices with embedded local security, but only a handful of true ZTE solutions exist today, and legacy devices add additional management complexity.
“Tech leaders must be able to identify the right use cases and quantify potential benefits, costs, and risks across multiple horizons,” says Brian Hopkins, Forrester VP, emerging tech portfolio. “They need to spread investments out, with shorter-term technologies delivering quick returns and longer-term bets requiring more effort, more foundational investment, and the capacity to manage more risk.”
Resources:
- Learn more about the top emerging technologies that will deliver ROI for enterprises.
- Read The Top 10 Emerging Technologies In 2024 report to gain insight into maturity trends, business value, important use cases, and risks associated with each technology (client access required).
- Register for a complimentary webinar that takes a deep dive into the 2024 list of emerging technologies and their use cases and benefits.
- Download Forrester’s complimentary guide for tech leaders to identify use cases and gain support for emerging technologies.
- Tech and data leaders can attend Forrester’s 2024 Technology & Innovation Summits in North America, EMEA, and Asia Pacific to learn how to align their IT strategy to their business goals to accelerate growth.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625049417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
